ELSEVIER

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Inhibition of reverse transcriptase and *Taq* DNA polymerase by compounds possessing the coumarin framework



A. Garro Hugo ^{a,*}, M. Manzur Jimena ^b, M. Ciuffo Gladys ^c, E. Tonn Carlos ^a, R. Pungitore Carlos ^{a,*}

- ^a INTEQUI-CONICET, Fac. Qca., Bioqca. y Fcia., Univ. Nac. de San Luis (U.N.S.L), Chacabuco y Pedernera, 5700 San Luis, Argentina
- ^b Área de Biología Molecular, Fac. Qca., Bioqca. y Fcia., Univ. Nac. de San Luis (U.N.S.L), Argentina
- ^c Instituto Multidisciplinario de Investigaciones Biológicas, IMIBIO-CONICET, Argentina

ARTICLE INFO

Article history:
Received 3 December 2013
Revised 19 December 2013
Accepted 24 December 2013
Available online 3 January 2014

Keywords: Coumarins Reverse transcriptase Polymerase Molecular target Inhibition

ABSTRACT

Coumarin derivatives were prepared using natural products isolated from plants belonging in the *Pterocaulon* genus (Asteraceae) and commercial drugs. Some molecules have displayed interesting activity against myeloid murine leukemia virus-reverse transcriptase (MMLV-RT) (compounds **20** and **28** produced inhibition with IC_{50} values of 38.62 and 50.98 μ M, respectively) and *Taq* DNA polymerase (analogues **13** and **14** produced inhibition with IC_{50} values of 48.08 and 57.88 μ M, respectively). Such inhibitors may have importance as antiretroviral chemotherapeutic agents and also in the development of anticancer drugs.

© 2013 Elsevier Ltd. All rights reserved.

Human Immunodeficiency Virus (HIV) is the viral agent of acquired immunodeficiency syndrome (AIDS), and at present, there is no effective vaccine against HIV. Reverse Transcriptase (RT) is an essential enzyme for retroviral replication, such as HIV as well as for other RNA infectious viruses like Human T lymphocyte virus. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS), a class of antiretroviral chemotherapeutic agents, act by binding to an allosteric pocket showing, generally, low toxicity. Another potential molecular target is DNA polymerases, which represent important cellular targets in the development of anticancer and antiviral agents.

Natural coumarins have attraction due to bioactive properties such as tumor promotion inhibitory effects, anti-bacterial activity, antituberculosis, anti-influenza, anti-alzheimer, anti-inflammatory, and as anti-coagulants. Coumarins and derivates exhibit potent inhibitory effects on HIV-1 replication in H9 lymphocytes and compounds isolated from Calophyllum inophyllum showed inhibitory activity against human RT. Cumarins and derivates are inhibit human DNA polymerase λ . The object of the present work was to examine the ability of compounds possessing the coumarin framework to inhibit RT from myeloid murine leukemia virus (MMLV) and Taq DNA polymerase.

For the present study we selected two plant species from genus *Pterocaulon* (Asteraceae); *P. virgatum* (L.) D.C and *P. alopecuroides* (L.) D.C, known as coumarin's producers. ^{16,17} We describe the isolation and characterization of four coumarins: sabandinine 1; 5-(3',3'-dimethylallyloxy)-6,7-methylendioxycoumarin 2; 7-(3'-methyl-2',3'-dihydroxybutoxy)-6,8-dimethoxycoumarin 3 and 7-(3'-methyl-2',3'-dihydroxybutoxy)-6-methoxycoumarin 4 (Fig. 1).

We evaluate the potential antiviral therapeutic properties from natural and semi-synthetic analogues derivatives. The family of compounds was screened by retro-transcription polymerase chain reaction (RT-PCR) and classical polymerase chain reaction (PCR) inhibition. ¹⁸

In order to increase the number of compounds for biological tests we performed chemical transformation over products $\bf 2$ and $\bf 4$. Thus, 7-(3'-methyl-2',3'-dihydroxybutoxy)-6-methoxycoumarin ($\bf 4$) was treated with H_2SO_4 in presence of acetone, leading to the formation of compound $\bf 5$, with a typical acetonide moiety with a yield of 93% (Scheme 1). This group is also present in natural coumarins $\bf 1$ and $\bf 2$, resembles in part their structure.

Besides, acetylating of hydroxyl groups in compound **4** was carried out in a regio-selective manner. Thus, secondary hydroxyl group was preferentially acetylated (**7**) to tertiary hydroxyl (**6**) when the reaction was carried out in the absence of DMAP. Using DMAP as a catalyst the per-O-acetylated derivative (**6**) was obtained as the sole product, with 94% yield (Scheme 1).

In another group of reactions the γ, γ -dimethylallyl moiety present in compound **2** was subjected to epoxidation whit m-CPBA to

^{*} Corresponding authors. Tel.: +54 2644 423789; fax: +54 2664 426711.

E-mail addresses: hugocanaya@yahoo.com.ar (A. Garro Hugo), crpungi@unsl. edu.ar (R. Pungitore Carlos).

Figure 1. Compounds isolated from P. virgatum and P. alopecuroides.

$$(ii)$$

$$(iii)$$

Scheme 1. Reagents and conditions: (i) H₂SO₄, acetone, rt; (ii) 2.3 equiv Ac₂O, Py, DMAP, rt; (iii) 1.0 equiv Ac₂O, Py, 0 °C-rt.

obtain the corresponding oxirane 8 and generate a new stereogenic center. Also, by a simple reduction using hydrogen and 5% palladium a hydrogenated derivative 9 was obtained with regioselection at carbons 2'-3' (63% yield). We also envisaged allylic oxidations, initially using KMnO₄ and ammonium salt to achieve the exchange of phases, giving a mixture of compounds 10 (59% yield) and 11 (33% yield). Now, employing SeO₂ to get a carbonyl function was possible to prepare a Michael acceptor 12 at the side chain. It is well known the high degree of reactivity of α,β -unsaturated carbonyls against the nucleophiles nitrogen, sulfur and oxygen, present in enzymes, or even the same DNA molecule. 19,20 In this reaction it was also observed the appearance of a more polar product 13, corresponding to a primary alcohol at the isoprenoid chain. It was also envisaged to introduce halogen atom (bromination) on the double bond, mainly at the γ , γ -dimethylallyl function. Simple addition of bromine performed with NBS in carbon tetrachloride or acetic acid furnished a complex mixture of compounds. Surprisingly, halohydrin 14 was obtained in 72% rather than the expected dibromoderivative. This result can be explained in case the dihalogenated product initially obtained could suffer SN₁ reaction on C-3' in the water washing process (Scheme 2). The different reactivity of carbons 2' and 3' can be explained considering the C-3' is a tertiary carbon, capable of forming a more stable carbocation that C-2'.

In another set of reactions we used commercial 4-hydroxy-coumarin **15**, 4-hydroxy-3-nitrocoumarin **16**, coumaranone **17**, 3-acetylcoumarin **18**, 3-hydroxycoumarin **19** and coumarin **20** to increase the number of derivatives for inhibition assays (Fig. 2). We were able to methylate the enol group of **15** using Me₂SO₄ as alkylation agent producing compound **21** (67% yield). In same substrate we can generate a benzoyl analogue (**22**) in a 57% yield, employing BzOCl. In order to incorporate a heteroatom on compound **15**, it

was subjected to reaction with methanesulfonyl chloride (23) (92% yield) and with p-chlorobenzoyl chloride (24) (78% yield) and both of them showed as white crystals (Scheme 3). However, compound **16** was only capable to reacting with this last protecting group, generating the derivative **25** (46% yield) (Scheme 4). This low reactivity of 16 may be explained by the high electro-drawing effect of the nitro group, which would decrease the nucleophilic character of the enol function. Finally, we proposed a prenylation reaction on 15 to achieve a structurally related derivative to the naturally 5-(3',3'-dimethylallyloxy)-6,7-methylendioxycoumarin 2. In this reaction, we obtained two products: the expected analogue 26 (59% yield) and a less polar dicarbonylic compound 27 (24% yield). Hybridization change and the incorporation of two isoprenoid chains, both on third position can be explained mainly by the substantial electron density present in this carbon and keto-enol equilibrium of 15. In the same way, we used allyl bromide in turbo cooler equipment, giving a mixture of compounds (28-30) with different degrees of substitution (Scheme 5). All synthesized compounds and natural coumarins isolated were well characterized by ¹H and ¹³C NMR.²¹

Different natural coumarins as well as synthetic analogs were found to display potent anti-HIV activity and can serve as potent NNRTIs in the development of anti-AIDS leads. ²² It has been amply documented that DNA polymerases and reverse transcriptases serve as molecular targets for antiviral chemotherapy. ²³ Assessment of the activity of Taq DNA polymerase was performed by PCR technique. In an initial screening we used a concentration equal to $500 \, \mu M$; the results revealed that analogues 13 and 14 produced inhibition with IC50 values of 48.08 ± 9.26 and $57.88 \pm 1.26 \, \mu M$, respectively. Against expectations, the derivative bearing a Michael acceptor 12 was not active. However, the alcohol 13 obtained during the same reaction, was active. Compound 10

Scheme 2. Reagents and conditions: (i) *m*-CPBA, K₂CO₃, Cl₂CH₂, 0 °C and dark conditions; (ii) H₂, Pd/C, Cl₂CH₂, rt; (iii) 1.1 equiv KMnO₄, THF/H₂O (7:3), diethyl-ammonium fluoride, rt; (iv) 0.75 equiv SeO₂, Cl₂CH₂, 2.0 equiv TBHP, 0-4 °C; (v) 2.2 equiv NBS, Cl₂CH₂, 0-4 °C.

Figure 2. Commercial coumarins used.

has a carbonyl group at side chain, and as **12** also shown inactive. On the other hand, the incorporation of bromide seems to be significant for protein recognition and inhibition, ^{24–26} because compound **11** also have a tertiary alcohol and similar stereo-electronic factors as **14**, but it was inactive. Compound **14** has a particular structural feature in their side chain. The bromine atom can act as a leaving group in a nucleophilic attack by nucleophilic residues of proteins. The presence of oxygen containing functional

Scheme 4. Reagents and conditions: (i) 4-Chlorobenzoyl chloride, TEA, Cl₂CH₂, rt.

groups at both C- β can lead to neighboring group participation in the formation of the intermediate carbocation. This situation would result in a higher rate to the nucleophilic substitution (S_N1) in relation to the intramolecular substitution reaction (S_{Ni}) giving rise to the epoxide. This center might be the determining factor in the inactivation of the enzyme. Moreover, in compound 12, where it would be possible to expect a conjugate Michael

Scheme 3. Reagents and conditions: (i) Me₂SO₄, K₂CO₃, acetone, 56 °C; (ii) BzOCl, TEA, Cl₂CH₂, rt; (iii) 1.3 equiv MsCl, 1.2 equiv Py, 0.6 equiv DMAP, Cl₂CH₂, rt; (iv) 4-chlorobenzoyl chloride, TEA, Cl₂CH₂, rt.

Scheme 5. Reagents and conditions: (i) 2.0 equiv γ,γ-dimethylallyl bromine, 1.5 equiv NaH, DMF, rt; (ii) 2.0 equiv allyl bromine, 1.5 equiv NaH, DMF, -20 °C.

Table 1Activity data of compounds against enzymes

	$IC_{50}^{a}(\mu M)$	
Compound	Taq DNA pol	RT-MMLV
13	48.08 ± 9.26	b
14	57.88 ± 1.26	b
20	No activity	38.62 ± 3.25
28	No activity	50.98 ± 1.79

^a Concentration that inhibits enzyme activity by 50%.

addition, the oxygen atom of the ether function can be protected from nucleophilic attack by the proximity of their unshared electron pairs to the electrophilic carbon. This situation has previously been reported for α,β -unsaturated cyclopentenone moieties in sesquiterpene lactones.²⁷ Finally, the similar values of activity obtained with products **13** and **14** could be partially attributed to their related polarity.

Furthermore, we used all compounds obtained (except 13 and 14 because the RT-PCR experiment involve the Tag DNA polymerase activity) to evaluate reverse transcription process using a concentration of 500 µM for initial screening. Herein could be observed that compound 20 and 28 produced inhibition with IC_{50} values of 38.62 \pm 3.25 and 50.98 \pm 1.79 μ M, respectively. These results indicate that in reverse transcription, simple molecules like coumarin and 28 are able to inhibit this event. Taking into account the structure, is hard to think that coumarins act recognizing the enzymatic active site. Probably they can place allosterically, for example at some hydrophobic pocket.²⁸ Furthermore, it is interesting to note that none of the naturally occurring compound was active against Taq DNA polymerase and RT-MMLV. However, these compounds are important synthons and skeletons for obtaining active compounds. Also, it is possible to observe that the compounds inhibit the DNA polymerase present methylendioxy ring; different from that observed with RT inhibitor compounds which do not possess the mentioned moiety. These results convert to the methylendioxy ring in necessary for activity against Taq DNA polymerases but it is not the only required condition because compounds as 1-2 and 10-12 are not active.

The aim of the present study was to evaluate the inhibition by coumarin, because of these compounds have showed important inhibitory activity against HIV-infected lymphocytes.²⁹ There is a high relationship between RNA dependent enzymes as RT-MMLV and DNA dependent polymerases like *Taq* polymerase. These

structures resemble a right hand domain and conserve amino acid sequence inside catalytic region.³⁰ We also found that some coumarins can inhibit the *Taq* DNA polymerase activity and in this way could be cataloged as new polymerase inhibitors (see Table 1). Taking into account the results from this Letter, it is possible to say that the coumarin analogs merit special attention as potential antivirals.

In summary, we have isolated four natural coumarins from *P. virgatum* and *P. alopecuroides* and prepare twenty semi-synthetic analogues besides commercial drugs. Their inhibitory activity against *Taq* DNA polymerase and MMLV-RT was evaluated and two molecules (compounds **13** and **14**) with similar structures showed inhibitory activity against *Taq* DNA polymerase. Also, coumarin (**20**) and compound **28** were able to inhibit the reverse transcriptase with interesting values of activity. Thus, novel leads from these coumarins can be further developed into potential chemotherapeutic agents in antiviral treatment.

Acknowledgments

This research was supported by CONICET (PIP 00628), UNSL (Project 7301 and 2-1412) and ANPCyT (PICT-10714, 9759). H.A.G. thank CONICET for post-doctoral fellowship. We wish to thank to Lic. Ferrari, Lic. Mascotti, Dr. Ardanáz and Dr. Rossomando for their help. C.R.P., G.M.C. and C.E.T. belong to CIC-CONICET. This work is a part of the doctoral thesis of H.A.G.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmcl.2013. 12.104.

References and notes

- Palella, F.; Baker, R.; Moorman, A.; Chmiel, J.; Wood, K.; Brooks, J.; Holmberg, S. Immune Def. Syndr. 2006, 43, 27.
- 2. Mehellou, Y.; De Clercq, E. J. Med. Chem. 2010, 53, 521.
- 3. Béthune, M. Antiviral Res. 2010, 85, 75.
- Pungitore, C.; Leon, L.; García, C.; Martín, V.; Tonn, C.; Padrón, J. Bioorg. Med. Chem. Lett. 2007, 17, 1332.
- Ito, C.; Itoigawa, M.; Katsuno, S.; Omura, M.; Tokuda, H.; Nishino, H. J. Nat. Prod. 2000, 63, 1218.
- 6. Wu, T.; Furukawa, H. J. Nat. Prod. 1982, 45, 718.
- Manvar, A.; Bavishi, A.; Radadiya, A.; Patel, J.; Vora, V.; Dodia, N.; Rawal, K.; Shah, A. Bioorg, Med. Chem. Lett. 2011, 21, 4728.
- 8. Yeh, J.-Y.; Coumar, M. S.; Horng, J.-T.; Shiao, H.-Y.; Lee, H.-L. *J. Med. Chem.* **2010**, 53, 1519.
- 9. Anand, P.; Singh, B.; Singh, N. Bioorg. Med. Chem. 2012, 20, 1175.

b It cannot be determinate.

- Lin, C.-M.; Huang, S.-T.; Lee, F.-W.; Kuo, H.-S.; Lin, M.-H. Bioorg. Med. Chem. 2006, 14, 4402.
- 11. Verso, M.; Agnelli, G. Thromb. Res. 2012, 129, 101.
- Xia, P.; Yin, Z. J.; Chen, Y.; Zhang, Q.; Zhang, B. N.; Xia, Y.; Yang, Z. Y.; Kilgore, N.;
 Wild, C.; Morris-Natschke, S. L.; Lee, K. H. Bioorg. Med. Chem. Lett. 2004, 14, 3341.
- Chen, Y.; Zhang, Q.; Zhang, B. N.; Xia, P.; Xia, Y.; Yang, Z. Y.; Kilgore, N.; Wild, C.; Morris-Natschke, S. L.; Lee, K. H. Bioorg. Med. Chem. 2004, 12, 6383.
- 14. Pungitore, C. Curr. Enzyme Inhib. 2008, 4, 194.
- Kamisuki, S.; Ishimaru, C.; Onoda, K.; Kuriyama, I.; Ida, N.; Sugawara, F.; Yoshida, H.; Mizushina, Y. Bioorg. Med. Chem. 2007, 15, 3109.
- 16. Maes, D.; Debenedetti, S.; De Kimpe, N. Biochem. Syst. Ecol. 2006, 34, 165.
- Alarcóna, R.; Pacciaroni, A.; Peñalozac, L.; Uriburuc, M.; Boemoc, A.; Sosa, V. Biochem. Syst. Ecol. 2010, 38, 1059.
- 18. **Experimental:** *PCR assays*: The assayed compounds were all dissolved in DMSO. The PCR master mixture consisted of 40 mM Trisacetate pH 8.3, 15 mM MgCl₂, 2.5 U of *Taq* DNA polymerase (Sigma–Aldrich), 20 mM each oligonucleotide primer, and 2.5 mM each desoxynucleotide triphosphate (dNTP). Inhibition studies were carried out with varying compound concentrations. All PCRs were done in 20 μL reaction volumes. The sequence of the sense primer was 5'-TAG AGC GTG AGG TCG ACA C-3', and the antisense primer, 5' TCA AGT TAG ACG TGG CCG TC 3'. Thermocycling conditions consisted of 35 cycles of denaturation at 95 °C for 1 min followed by primer annealing at 56 °C and primer extension at 72 °C for 90 seg.

RT-PCR assays: The inverse transcription process consisted of 1 μ g RNA dissolved in 4 μ L of commercial buffer and 2.0 U of MMLV-RT (Sigma-Aldrich), 20 μ M random primers, and 1.0 mM each desoxynucleotide triphosphate (dNTP). Inhibition studies were carried out with varying compound concentrations and adding compounds in this stage. All RT-PCRs were done in 6.8 μ L reaction volumes. Reaction conditions consisted of heating at 70 °C for 10 min and incubating 1 h at 56 °C.

Analysis of PCR products: Relative intensities of ethidium bromide stained PCR products were analyzed by using the optical scanner and the image program. The image of stained agarose gel was captured using a photography camera Kodak 2320 and then was scanned (Hewlett–Packard 3200 C). The digitized band images were processed using the Image processing program (Scion Image, public domain program); IC₅₀ values were determined by the GraphPad Prism program.

- 19. Kumar, V.; Mahajana, A.; Chibale, K. Bioorg. Med. Chem. 2009, 17, 2236.
- 20. Romanenko, V.; Kukhar, V. Tetrahedron 2008, 64, 6153.
- Spectroscopy data for natural compounds 1-4 and active tested compounds 13. 14. 20. 28.

Sabandinine (1): 1 H NMR (200 MHz, Cl₃CD) 4.14 (s, 3H), 6.01 (s, 2H), 6.18 (d, 1H, J = 9.4 Hz), 6.53 (br m, 1H) 7.94 (d, 1H, J = 9.4 Hz). 13 C NMR from HSQC (50.6 MHz, Cl₃CD) 59.00, 92.12, 101.80, 111.96, 138.70.

5-(3',3'-Dimethylallyloxy)-6,7-methylendioxycoumarin (2): ¹H NMR (200 MHz, Cl₃CD) 1.78–1.73 (br m, 6H), 4.83 (br m, 1H), 4.87 (d, 1H, J=7.2 Hz), 5.47 (br m,

1H), 6.01 (s, 2H), 6.19 (d, 1H, J = 9.6 Hz), 6.52 (s, 1H), 7.96 (d, 1H, J = 9.6 Hz); 13 C NMR from HSQC (50.6 MHz, Cl₃CD) 17.00, 29.30, 69.00, 92.52, 101.60, 111.88, 119.53, 139.30.

7-(3'-Methyl-2',3'-dihydroxybutoxy)-6,8-dimethoxycoumarin (3): 1 H NMR (200 MHz, Cl₃CD) 1.40–1.20 (br m, 6H), 3.82 (br m, 1H), 3.84 (s, 3H), 4.01 (s, 3H), 4.23–4.11 (br m, 2H), 6.24 (d, 1H, J = 9.4 Hz), 6.62 (s, 1H), 7.86 (d, 1H, J = 9.4 Hz); 13 C NMR from HSQC (50.6 MHz, Cl₃CD) 25.00, 26.50, 61.57, 71.11, 75.46, 96.90, 117.99, 138.93.

7-(3'-Methyl-2',3'-dihydroxybutoxy)-6-methoxycoumarin (4): 1 H NMR (200 MHz, Cl₃CD) 1.34–1.26 (br m, 6H), 3.89 (br m, 1H), 3.92 (s, 3H), 4.30–4.15 (br m, 2H), 6.25 (d, 1H, J = 9.8 Hz), 6.85 (s, 1H), 6.91 (br m, 1H), 7.62 (d, 1H, J = 9.8 Hz); 13 C NMR from HSQC (50.6 MHz, Cl₃CD) 26.00, 27.50, 68.40, 70.60, 74.80, 97.60, 103.40, 110.99, 142.30.

74.80, 97.80, 103.40, 110.35, 142.50.

5-(3'-Methyl-4'-hydroxy-2'-butenoxy)-6,7-methylendioxy coumarin (13): ¹H

NMR (200 MHz, Cl₃CD) 1.82 (s, 3H), 4.11 (s, 2H), 4.95 (d, 2H, J = 6.8 Hz), 5,77

(t, 1H, J = 4.4 Hz) 6.02 (s, 2H), 6.18 (d, 1H, J = 9.6 Hz), 6.54 (s, 1H), 7.96 (d, 1H, J = 9.6 Hz); ¹³C NMR from HSQC (50.6 MHz, Cl₃CD) 10.00, 68.00, 69.10, 93.02, 101.80, 112.50, 120.76, 141.15.

 $5\text{-}(2'\text{-}Bromine\text{-}3'\text{-}hydroxy\text{-}3'\text{-}methyl\text{-}butiloxy)\text{-}6,7\text{-}methylendioxycoumarin} \end{cases} \begin{center} (14): 1H NMR (200 MHz, Cl_3CD) 1.44$-1.25 (br m, 6H), 3.34 (br m, 1H), 4.22 (dd, 1H, <math display="inline">J$ = 3.2; 5.6 Hz), 4.50 (dd, 1H, J = 8.8; 2.8 Hz), 5.02 (dd, 1H, J = 3.2; 8.0 Hz) 6.05 (s, 2H), 6.22 (d, 1H, J = 9.8 Hz), 6.56 (s, 1H), 8.12 (d, 1H, J = 9.8 Hz); 13C NMR from HSQC (50.6 MHz, Cl_3CD) 30.00, 64.20, 74.10, 93.22, 101.90, 111.92, 139.80. \end{center}$

2-*H*-1-Benzopiran-2-ona (**20**): ¹H NMR (200 MHz, Cl_3CD) 6.45 (d, 1H, J = 9.4 Hz), 7.31 (br m, 1H), 7.35 (d, 1H, J = 8.1 Hz), 7.52 (d, 1H, J = 7.8 Hz), 7.56 (br m, 1H), 7.73 (d, 1H, J = 9.4 Hz); ¹³C NMR from HSQC (50.6 MHz, Cl_3CD) 115.99, 116.18, 123.72, 127.17, 131.12, 142.73.

4-Hydroxy-3-allyloxy-coumarin (**28**): 1 H NMR (200 MHz, Cl₃CD) 3.50 (d, 2H J = 6.8 Hz), 5.27 (br m, 2H), 6.03 (br m, 1H), 7.27 (br m, 2H), 7.51 (dd, 1H, J = 1.6; 7.2 Hz) 7.81 (d, 1H J = 8.0 Hz); 13 C NMR from HSQC (50.6 MHz, Cl₃CD) 29.00, 116.15, 117.20, 121.89, 123.05, 134.23, 135.76.

- 22. Kostova, I. Curr. HIV Res. 2006, 4, 347.
- 23. Yasuhara-Bella, J.; Lu, Y. Antiviral Res. 2010, 86, 231.
- Woods, J.; Hadfield, J.; Mc Grown, A.; Fox, B. Bioorg. Med. Chem. Lett. 1993, 5, 333.
- Oh, Ki-Bong; Lee, J. H.; Lee, J. W.; Yoon, K.-M.; Chung, S.-C.; Jeon, H. B.; Shin, J.; Lee, H.-S. Bioorg. Med. Chem. Lett. 2009, 19, 945.
- Suzuki, T.; Moriwaki, N.; Kurokawa, K.; Inukai, M. Bioorg. Med. Chem. Lett. 2009, 19, 3217.
- 27. Giordano, O.; Pestchanker, M.; Guerreiro, E.; Saad, J.; Enriz, R.; Rodríguez, A.; Jáuregui, E.; Guzmán, J.; María, A.; Wendel, G. J. Med. Chem. 1992, 35, 2452.
- 28. Stringner, S.; Yang, S.; Gordon, M.; Cragg, D.; Newman, J.; Bader, J. J. Nat. Prod. 2001, 64, 265.
- Wang, Y.; Huang, S.; Xia, P.; Xia, Y.; Yang, Z.; Kilgore, N.; Morris-Natschkeb, S.; Lee, K. Bioorg. Med. Chem. Lett. 2007, 17, 4316.
- 30. Otsuka, J.; Kikuchi, N.; Kojima, S. Biochim. Biophys. Acta 1999, 1434, 221.